We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-13.83%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.51B
AUM Growth
-$1.01B
(-13%)
Cap. Flow
+$139M
Cap. Flow
% of AUM
2.14%
Top 10 Holdings %
Top 10 Hldgs %
20.49%
Holding
891
New
87
Increased
331
Reduced
275
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$60.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$30.7M |
| 3 |
Biogen
BIIB
|
+$19.7M |
| 4 |
Mastercard
MA
|
+$18.7M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSRO
TESARO, Inc.
TSRO
|
+$32.8M |
| 2 |
Ecopetrol
EC
|
+$29.1M |
| 3 |
AET
Aetna Inc
AET
|
+$20.2M |
| 4 |
ExxonMobil
XOM
|
+$19.6M |
| 5 |
Amgen
AMGN
|
+$19.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.31% |
| 2 | Technology | 15.37% |
| 3 | Financials | 11.61% |
| 4 | Consumer Discretionary | 8.19% |
| 5 | Communication Services | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NFX
551
DELISTED
Newfield Exploration
NFX
| $1.13M | 0.02% |
+77,219
| New | +$1.55M |
|
552
Globe Life
GL
$13.5B
| $1.13M | 0.02% |
15,147
-955
| -6% | -$79.4K |
|
553
AngioDynamics
ANGO
$562M
| $1.13M | 0.02% |
56,000
| – | – |
|
554
Warner Bros
WBD
$64.6B
| $1.12M | 0.02% |
45,169
+3,604
| +9% | +$110K |
|
|
DISCK
555
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $1.12M | 0.02% |
48,356
+7,350
| +18% | +$205K |
|
556
Federal Realty Investment Trust
FRT
$10.9B
| $1.11M | 0.02% |
9,393
+1,346
| +17% | +$169K |
|
|
SJR
557
DELISTED
Shaw Communications Inc.
SJR
| $1.11M | 0.02% |
61,205
+44,699
| +271% | +$839K |
|
558
Assurant
AIZ
$13.7B
| $1.1M | 0.02% |
12,330
-313
| -2% | -$30.6K |
|
559
Idexx Laboratories
IDXX
$42.9B
| $1.1M | 0.02% |
5,924
| – | – |
|
560
Brown-Forman Class B
BF.B
$12B
| $1.09M | 0.02% |
23,011
+1,219
| +6% | +$57.9K |
|
561
Regency Centers
REG
$15B
| $1.09M | 0.02% |
18,583
| – | – |
|
562
Aurinia Pharmaceuticals
AUPH
$1.97B
| $1.07M | 0.02% |
157,500
| – | – |
|
|
ANSS
563
DELISTED
Ansys
ANSS
| $1.02M | 0.02% |
7,134
+4,553
| +176% | +$707K |
|
|
WCG
564
DELISTED
Wellcare Health Plans, Inc.
WCG
| $1.01M | 0.02% |
+4,292
| New | +$1.15M |
|
565
Equifax
EFX
$20.3B
| $1M | 0.02% |
10,791
+471
| +5% | +$50.1K |
|
|
NXEO
566
DELISTED
Nexeo Solutions, Inc. Common Stock
NXEO
| $1M | 0.02% |
116,732
| – | – |
|
567
Vulcan Materials
VMC
$36.3B
| $1M | 0.02% |
10,124
-1,058
| -9% | -$107K |
|
|
ABMD
568
DELISTED
Abiomed Inc
ABMD
| $983K | 0.02% |
3,024
+184
| +6% | +$63.9K |
|
|
EGRX
569
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $967K | 0.01% |
24,000
| – | – |
|
|
SRRA
570
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $950K | 0.01% |
18,000
| – | – |
|
571
Targa Resources
TRGP
$60.4B
| $949K | 0.01% |
26,343
+3,353
| +15% | +$162K |
|
572
Robert Half
RHI
$3.61B
| $944K | 0.01% |
16,498
-975
| -6% | -$59.8K |
|
|
AMTD
573
DELISTED
TD Ameritrade Holding Corp
AMTD
| $927K | 0.01% |
18,935
| – | – |
|
574
Insmed
INSM
$23.2B
| $926K | 0.01% |
70,567
-150
| -0.2% | -$2.39K |
|
575
Corpay
CPAY
$24.2B
| $915K | 0.01% |
4,929
-31,649
| -87% | -$6.19M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2018 Portfolio in Review
As of Q4 2018, Candriam SCA held 891 positions worth $6.51B, down 13% from $7.52B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA's Q4 2018 filing shows 87 new, 331 increased, 275 reduced and 84 closed positions. Its largest new stake was Azul: 501,000 shares worth $13.9M. The largest sale was TESARO, Inc., an estimated $32.8M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q4 2018 buy was Azul: 501,000 shares worth $13.9M.
- Candriam SCA added most to Celgene Corp in Q4 2018, an estimated $60.9M increase.
- Candriam SCA's biggest Q4 2018 reduction was TESARO, Inc., cutting an estimated $32.8M.
- Candriam SCA fully exited Aetna Inc in Q4 2018, selling an estimated $20.2M.
- Candriam SCA's ten largest holdings make up 20% of its $6.51B portfolio in Q4 2018.
- Candriam SCA opened 87 new positions and closed 84 in Q4 2018.
- Candriam SCA's portfolio value fell 13% quarter-over-quarter to $6.51B.
Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.